Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials

被引：0
|
作者：
T. T. Zhang
R. M. Wang
Z. Yang
G. B. Chen
机构：
[1] The First People’s Hospital of Shangqiu,Department of Oncology
[2] The First People’s Hospital of Shangqiu,Department of General Surgery
[3] The First Affiliated Hospital of Zhengzhou University,Department of Gastrointestinal Surgery
来源：
Clinical and Translational Oncology | 2016年 / 18卷
关键词：
Non-small-cell lung cancer; EGFR-TKIs; Molecular targeted agents; Angiogenesis inhibitors; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：576 / 581
页数：5
相关论文
共 50 条
  • [21] EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance
    Fogli, Stefano
    Polini, Beatrice
    Del Re, Marzia
    Petrini, Iacopo
    Passaro, Antonio
    Crucitta, Stefania
    Rofi, Eleonora
    Danesi, Romano
    PHARMACOGENOMICS, 2018, 19 (08) : 727 - 740
  • [22] Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis
    Min Ying
    Xiaoxia Zhu
    Kexu Chen
    Zhou Sha
    Longhua Chen
    Journal of Cancer Research and Clinical Oncology, 2015, 141 : 1427 - 1439
  • [23] KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies
    Mao, Chen
    Qiu, Li-Xin
    Liao, Ru-Yan
    Du, Fang-Bing
    Ding, Hong
    Yang, Wan-Chun
    Li, Jin
    Chen, Qing
    LUNG CANCER, 2010, 69 (03) : 272 - 278
  • [24] Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer A meta-analysis
    Huang, Lei
    Huang, Hao
    Zhou, Xiao-Ping
    Liu, Jin-Feng
    Li, Chun-Rong
    Fang, Min
    Wu, Jun-Rong
    MEDICINE, 2019, 98 (43)
  • [25] Treatment with EGFR-TKIs in Non Small Cell Lung Cancer Patients. The Impact of EGFR Mutations
    Garcia Manrique, Teresa
    Carrillo De Albornoz, Rosario
    Milena Vargas, Ana
    Alamo De la Gala, M. Carmen
    Grueso Lopez, Ana Maria
    Barros Perez, M. Mar
    Vicente Baz, David
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S408 - S408
  • [26] Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
    Li, Ruijian
    Li, Weiyi
    Zhang, Fang
    Li, Shanshan
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
  • [27] Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
    Ruijian Li
    Weiyi Li
    Fang Zhang
    Shanshan Li
    European Journal of Medical Research, 28
  • [28] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer
    Aguilar-Serra, J.
    Gimeno-Ballester, V
    Pastor-Clerigues, A.
    Milara, J.
    Trigo-Vicente, C.
    Cortijo, J.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 637 - 646
  • [29] The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
    Bai, Hao
    Xiong, Liwen
    Han, Baohui
    ONCOTARGETS AND THERAPY, 2017, 10 : 2335 - 2340
  • [30] Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients
    Chen, Rui-Lian
    Sun, Ling-Ling
    Cao, Yang
    Chen, Han-Rui
    Zhou, Jing-Xu
    Gu, Chu-Ying
    Zhang, Ying
    Wang, Si-Yu
    Hou, Wei
    Lin, Li-Zhu
    FRONTIERS IN ONCOLOGY, 2021, 11
12345